Quick answer: Vitamin K2 (menaquinone) is the form of vitamin K responsible for directing calcium to bone and teeth while preventing arterial calcification — a critical distinction from vitamin K1 (phylloquinone), which primarily serves the coagulation cascade. The MK-7 form of K2 has a half-life of 72 hours vs 1-2 hours for MK-4, producing significantly higher and more stable tissue concentrations. The Rotterdam Study (n=4,807) found that the highest tertile of K2 intake was associated with 57% lower risk of aortic calcification, 52% lower cardiovascular mortality, and 26% lower all-cause mortality compared to the lowest tertile (Geleijnse 2004, Journal of Nutrition). The therapeutic protocol: K2 MK-7 100-200mcg/day in conjunction with vitamin D3, magnesium, and calcium-from-food (not supplements).
Vitamin K1 vs K2: Two Vitamins with Completely Different Functions
Vitamin K is not a single compound but a family of fat-soluble vitamins that share the naphthoquinone ring structure but differ critically in their side chains and biological functions. Vitamin K1 (phylloquinone) is found in dark leafy greens (kale, spinach, broccoli) and is rapidly cleared from circulation (half-life 1-2 hours). Its primary role is hepatic: activating clotting factors II, VII, IX, X, and anticoagulant proteins C and S. This is why warfarin (a K1 antagonist) is used as an anticoagulant — and why K2’s cardiovascular benefits operate through an entirely different mechanism.
Vitamin K2 (menaquinone) exists in several sub-forms distinguished by the length of their isoprene side chain: MK-4 through MK-13. MK-4 (produced from K1 in animal tissues) and MK-7 (produced by bacteria, particularly Bacillus subtilis natto in fermented soybeans) are the most clinically studied. The critical pharmacokinetic distinction: MK-7 has a plasma half-life of 72 hours, compared to 1-2 hours for MK-4 and K1. This extended half-life means that a single daily dose of MK-7 maintains stable K2 tissue concentrations 24 hours/day, while MK-4 must be taken in multiple doses of 15mg or higher to achieve comparable tissue levels. For daily supplementation, 100-200mcg of MK-7 is functionally superior to most MK-4 preparations available in standard supplement doses (45-180mcg), though high-dose MK-4 protocols (45mg/day, as used in Japanese osteoporosis drug menatetrenone) have separate evidence.
Carboxylation of Vitamin K-Dependent Proteins: The Core Mechanism
K2’s biological function is remarkably specific: it serves as the essential cofactor for the enzyme gamma-glutamyl carboxylase (GGCX), which adds carboxyl groups to glutamate residues on vitamin K-dependent proteins (VKDPs), converting them to gamma-carboxyglutamate (Gla) residues. This carboxylation is required for the proteins to become biologically active. Without adequate K2, VKDPs are produced in their undercarboxylated, inactive form — unable to perform their calcium-binding functions.
The two VKDPs most critical to the K2 story are osteocalcin (bone Gla protein, BGP) and matrix Gla protein (MGP). Carboxylated osteocalcin incorporates into the hydroxyapatite matrix of bone, providing tensile strength and regulating crystal formation. Carboxylated MGP inhibits calcium deposition in arterial walls — it is the most potent inhibitor of vascular calcification identified in biology (Price 1998, Journal of Biological Chemistry demonstrated that MGP-knockout mice develop severe arterial calcification and die within 2 months of birth). Undercarboxylated MGP (ucMGP) is the direct biomarker of functional K2 deficiency, and circulating ucMGP is one of the strongest predictors of cardiovascular calcification risk ever identified.
Additional vitamin K-dependent proteins with emerging clinical significance: Gas6 (growth arrest-specific gene 6 — regulates cell survival and inflammation), Protein S (anticoagulant — K2 deficiency impairs both Protein S activity and MGP function simultaneously), periostin (extracellular matrix protein in bone and cartilage), and GRP (Gla-rich protein — a recently identified MGP-related calcification inhibitor). The more VKDPs are characterized, the broader K2’s biological significance becomes.
Vitamin K2 and Cardiovascular Disease: The Rotterdam Evidence
The Rotterdam Study prospective cohort (Geleijnse 2004, Journal of Nutrition) remains the foundational human evidence for K2’s cardiovascular role. In 4,807 subjects without cardiac history at enrollment, dietary vitamin K2 intake (but not K1) was inversely associated with coronary heart disease mortality, cardiovascular mortality, and all-cause mortality, as well as aortic calcification. The highest tertile of K2 intake had a 57% lower risk of severe aortic calcification (OR 0.43), 52% lower risk of coronary heart disease death (RR 0.48), and 26% lower all-cause mortality compared to the lowest tertile. No comparable association was seen for vitamin K1 intake — confirming that the effect was specific to K2’s extrahepatic calcium-regulating functions rather than general vitamin K status.
The PROSPECT-EPIC cohort (Gast 2009, Nutrition, Metabolism and Cardiovascular Disease) in 16,057 Dutch women confirmed: K2 intake was significantly inversely associated with coronary heart disease risk (RR 0.91 per 10mcg/day K2 increase), while K1 showed no relationship. The Leiden Longevity Study and subsequent mechanistic studies in valve calcification, chronic kidney disease, and diabetes have consistently replicated the K2-cardiovascular calcification relationship.
The mechanistic narrative: MGP is constitutively expressed in vascular smooth muscle cells as a calcification defense. When K2 is insufficient, MGP is produced but remains undercarboxylated and non-functional — arterial calcium deposition proceeds unchecked. This is the mechanism behind the disturbing observation that statins reduce cardiovascular events but increase calcification score on CT angiography (Saremi 2012) — statin-induced mevalonate pathway inhibition depletes the prenyl groups required for K2 recycling, potentially accelerating MGP undercarboxylation. Whether K2 supplementation should be co-prescribed with statins is an active research question.
Vitamin K2 and Bone Health: Osteocalcin and Beyond
Osteocalcin is the most abundant non-collagen protein in bone matrix — it is produced by osteoblasts and incorporates into bone hydroxyapatite to regulate crystal size, mineralization rate, and bone matrix organization. Carboxylation by K2 is required for osteocalcin to bind hydroxyapatite with high affinity. Undercarboxylated osteocalcin (ucOC) — which circulates when K2 is insufficient — cannot be incorporated into bone matrix effectively, reducing bone quality even when calcium and vitamin D are adequate.
The clinical significance of ucOC as a bone quality marker (as opposed to bone quantity measured by DEXA): multiple studies show that hip fracture risk is predicted more strongly by circulating ucOC levels than by bone mineral density alone. Schaafsma and colleagues (2000) demonstrated that MK-7 supplementation (45mcg/day as natto) significantly reduced ucOC levels and improved bone mineral density in postmenopausal women over 12 months. The ECKO trial (Cheung 2008, PLOS Medicine) using MK-4 at 45mg/day showed significant reduction in fracture risk but not BMD — suggesting K2 improves bone quality (fracture resistance) through mechanisms beyond simple mineralization density.
Japanese menatetrenone (MK-4, 45mg/day) is approved as a prescription osteoporosis treatment in Japan, where it has been used for decades. The Japanese trial data (Shiraki 1996, n=241 — fracture reduction; Sato 1998, n=60; Ushiroyama 1995) consistently show reduction in vertebral fracture rate independent of BMD changes. The Vitamin K2 Therapy for Postmenopausal Osteoporosis study (VKTOP, 2013) with MK-7 100mcg/day for 3 years (n=244) showed significant increases in carboxylated osteocalcin, reduction in ucOC, and preservation of bone stiffness indices on quantitative ultrasound — benefits not seen in the placebo group.
The Vitamin D3–K2 Synergy: Why They Must Be Taken Together
The vitamin D3-K2 relationship is not marketing synergy — it is a biologically necessary pairing with clinical evidence supporting combined supplementation over either alone. Vitamin D3 stimulates intestinal calcium absorption (increasing circulating calcium 2-3 fold) and upregulates osteocalcin gene expression in osteoblasts. Without adequate K2 to activate (carboxylate) the osteocalcin being produced, the calcium mobilized by D3 cannot be incorporated effectively into bone — and may instead deposit in soft tissues including arteries. This is the mechanism behind the concern that high-dose vitamin D supplementation without K2 could theoretically worsen arterial calcification in K2-deficient individuals.
The Vitamin D and Omega-3 Trial (VITAL, Manson 2019, NEJM) found that high-dose vitamin D3 supplementation (2,000 IU/day) did not reduce major cardiovascular events — a puzzling null result given vitamin D’s mechanistic connections to cardiovascular health. K2 co-depletion in study populations may partly explain why vitamin D intervention trials have been disappointing for cardiovascular endpoints while observational studies consistently associate higher 25-OH-D levels with lower cardiovascular risk. In clinical practice, vitamin D3 should be co-prescribed with K2 MK-7 to ensure that the calcium mobilized by D3 is directed to bone rather than arteries. The standard co-dosing protocol from our vitamin D deficiency protocol: D3 2,000-5,000 IU/day with K2 MK-7 100-200mcg/day.
Vitamin K2 and Diabetes: The Osteocalcin-Adiponectin Connection
Osteocalcin is not merely a passive bone matrix protein — it functions as a hormone. Uncarboxylated osteocalcin (the form that circulates when K2 is adequate and bone remodeling is active) stimulates beta-cell proliferation and insulin secretion (through GPRC6A receptor signaling on pancreatic beta cells), increases insulin sensitivity in muscle and fat (through adiponectin upregulation), and promotes energy expenditure (Ferron 2008, Cell). This osteocalcin endocrine axis provides another mechanism by which K2 status influences metabolic health beyond calcium regulation.
Epidemiological data support this mechanism: the MORGEN cohort found inverse associations between K2 intake and incident type 2 diabetes (Beulens 2010, Diabetes Care — RR 0.77 for highest vs lowest quartile of K2 intake), and multiple observational studies have found lower serum osteocalcin levels in type 2 diabetes patients compared to controls. Whether therapeutic K2 supplementation improves glycemic control in established diabetes requires larger RCT evidence, but the mechanistic pathway through osteocalcin hormone signaling is compelling and consistent with the observational data.
Dietary Sources of Vitamin K2
The most concentrated dietary source of K2 by far is natto — fermented soybeans produced by Bacillus subtilis natto fermentation. A 100g serving of natto contains approximately 1,000mcg of K2 (predominantly MK-7), explaining why Japan’s natto-consuming regions have significantly lower rates of osteoporosis and cardiovascular calcification than non-consuming regions. However, natto’s texture and flavor (described as stringy, pungent, and acquired) make it culturally unfamiliar outside Japan.
Other significant food sources: hard and soft cheeses (particularly Gouda and Brie, which contain MK-8 and MK-9 primarily — 49-74mcg per 100g), egg yolks (MK-4, 15-32mcg per 100g), goose liver (369mcg/100g — exceptional concentration), chicken liver (14mcg/100g), grass-fed butter (MK-4, 15mcg/100g), and fermented foods including sauerkraut and certain fermented vegetables. The critical insight: K2 content of animal products reflects the K1 content and type of feed the animals consumed. Grass-fed and pasture-raised animals have substantially higher K2 content than grain-fed; wild-caught fatty fish contain modest amounts of MK-4; factory-farmed chicken and eggs from caged hens contain minimal K2.
Most Western diets provide 10-20mcg of K2/day — far below the 32-45mcg/day in the lowest protective tertiles of the Rotterdam Study, and well below the 100-200mcg/day that fully suppresses circulating ucMGP (the biomarker of arterial calcification risk) in intervention trials. Supplementation is therefore effectively necessary for most people not consuming natto or large quantities of high-quality fermented dairy and organ meats.
Frequently Asked Questions
Does vitamin K2 interact with blood thinners?
Vitamin K2 (MK-7 at standard supplemental doses of 100-200mcg/day) does meaningfully interact with warfarin (coumadin). Warfarin works by blocking vitamin K epoxide reductase — preventing K recycling and thus inhibiting activation of K-dependent clotting factors. Supplemental K2 can reduce warfarin’s anticoagulant effect and raise INR, requiring warfarin dose adjustment. The key point: this is not an absolute contraindication but a pharmacokinetic interaction requiring physician management. For patients on warfarin who want K2 supplementation, maintaining a consistent, stable daily dose of K2 (rather than variable amounts) allows warfarin dosing to be adjusted accordingly. Newer anticoagulants (DOACs — apixaban, rivaroxaban, dabigatran) work through K-independent mechanisms (direct factor Xa or thrombin inhibition) and are not affected by K2 supplementation. If you are on any anticoagulant, discuss K2 supplementation with your prescribing physician before starting.
What is the difference between MK-4 and MK-7?
MK-4 and MK-7 are both menaquinone forms of vitamin K2 with the same VKDP carboxylation function, but they differ importantly in pharmacokinetics and origin. MK-4 has a plasma half-life of 1-2 hours — meaning it must be taken multiple times daily at high doses (typically 15-45mg in studies, not mcg) to maintain steady-state tissue concentrations. MK-7 has a half-life of 72 hours, maintaining stable concentrations at 100-200mcg once daily. MK-4 is produced endogenously from K1 conversion in certain tissues, while MK-7 is produced primarily by bacteria (especially in natto fermentation). For general supplementation at practical daily doses, MK-7 is superior due to its longer half-life and the substantially lower dose required. High-dose MK-4 (45mg/day) is approved as a prescription osteoporosis drug in Japan and has extensive fracture reduction data, but this dose is not available in most over-the-counter supplements. The practical recommendation: MK-7 100-200mcg/day for most supplementation purposes; high-dose MK-4 only under physician guidance for specific clinical indications.
Can vitamin K2 reverse arterial calcification?
The evidence suggests K2 can slow calcification progression and may contribute to partial regression in some contexts, but “reversal” of established calcification is not established in humans. The ECAC pilot study (Dalmeijer 2012) showed that K2 supplementation reduced circulating ucMGP and slowed carotid intima-media thickness progression. The most relevant data comes from dialysis patients — who have severely impaired K2 status and extremely high vascular calcification burden: the VitaVasK trial (Brandenburg 2017, Kidney International) showed that MK-7 supplementation reduced ucMGP by 68% and slowed coronary calcification progression vs placebo. The LeCAP trial (Knapen 2015) demonstrated that 180mcg MK-7 for 3 years significantly improved indices of vascular stiffness in healthy postmenopausal women — the first prospective evidence that K2 improves vascular function. Prevention of calcification progression is the realistic clinical goal; complete regression of established calcification requires more evidence.
How much vitamin K2 do I need per day?
The optimal daily dose of K2 MK-7 for most adults is 100-200mcg/day — the range used in the majority of clinical trials demonstrating cardiovascular and bone benefits. This dose fully suppresses circulating ucMGP (the arterial calcification biomarker) in most healthy adults. Individuals with existing vascular calcification, renal disease, or chronic inflammatory conditions may benefit from the higher end of this range or higher doses under physician guidance. The adequate intake for vitamin K established by nutrition authorities (90mcg/day for women, 120mcg/day for men) was set primarily based on K1 coagulation data and does not reflect the K2 dose required for optimal VKDP carboxylation in bone and vasculature — meaningful extrahepatic K2 activity requires supplemental MK-7 for the majority of people not consuming natto. The most practical protocol: K2 MK-7 100-200mcg/day with the main meal, co-administered with vitamin D3 and a fat-containing food (both are fat-soluble and require dietary fat for absorption).
Vitamin K2 represents one of the most cost-effective and clinically significant nutritional interventions available — addressing the calcium paradox (weak bones and stiff arteries simultaneously) through a single mechanism of VKDP carboxylation. If you would like to discuss your cardiovascular calcification risk, bone health status, and a personalized K2 protocol, contact our office at (810) 206-1402 to schedule a consultation.